Ishita Pharma -

Company snapshot

ISTA Pharma is a pharma organization headquartered in GB. Primary therapeutic focus areas include Ependymoma, Medulloblastoma, chronically occluded coronary artery, Hereditary Angioedema, Acute kidney injury, knee osteoarthritis. NovaPharmaNews links 8 clinical program(s), 0 drug profile(s), and 0 patent record(s) to this entity from public FDA, EMA, ClinicalTrials.gov, and USPTO sources. Pipeline phase mix: phase 3 (7), phase 2 (1).

• 8 active pipeline program(s) linked via ClinicalTrials.gov.
• 8 trial update(s) in the last 12 months.

Public regulatory, clinical, patent, and corporate records for Ishita Pharma -. Not investment advice.

Recent activity

Latest pipeline, patent, and corporate events for Ishita Pharma -.

1. Jun 8, 2026 Clinical update

   Etude DAPT-CTO — Phase 3

2. Jun 8, 2026 Clinical update

   RCAPHM19_0374 — Phase 3

3. Jun 8, 2026 Clinical update

   RCAPHM18_0018 — Phase 3

4. Jun 8, 2026 Clinical update

   MICROPREP III — Phase 3

5. Jun 8, 2026 Clinical update

   MEPENDAX — Phase 2

View all clinical trial activity →

• What is Ishita Pharma -?

  ISTA Pharma is a pharma organization headquartered in GB. Primary therapeutic focus areas include Ependymoma, Medulloblastoma, chronically occluded coronary artery, Hereditary Angioedema, Acute kidney injury, knee osteoarthritis. NovaPharmaNews links 8 clinical program(s), 0 drug

• Is Ishita Pharma - publicly traded?

  Ishita Pharma - appears in our database through regulatory marketing authorisation or clinical trial sponsor records; a US listed ticker is not shown for this entity.

• What drugs does Ishita Pharma - develop or market?

  We link 19 drug profile(s) where Ishita Pharma - is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/ista-pharma-limited#company-drugs.

• What are the latest developments for Ishita Pharma -?

  In the last 12 months our linked public records show 8 trial program update(s) and 0 US patent grant(s) tied to this profile.

• What therapeutic areas does Ishita Pharma - focus on?

  Ishita Pharma - focuses on Ependymoma, Medulloblastoma, chronically occluded coronary artery, Hereditary Angioedema based on our analysis of their pipeline programs and drug development activities.